Pediatric Oncology: Summary of Guidances and Meetings
Guidances
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Meetings
15 Sep: Pediatric Advisory Committee
Will discuss pediatric-focused safety reviews for medications related to acute dystonia associated with ADHD, acute hyperkinetic movement disorder associated with combined use of ADHD stimulants and antipsychotics
22-23 Oct: Pediatric Dose Selection Public Workshop ($50)
Will discuss current methods and future approaches, and how to address gaps in pediatric dose selection that occur because of an inability to perform certain studies in pediatric patients
Categories
- Blog Posts (56)
- Guest Blogs (8)
- Member Blogs (23)
- Survivorship Matters Blog (7)
- CAC2 News (13)
- Collaborative Achievements (13)
- Community News (107)
- Research Explained (6)
- Webinars (59)
Tags
#CancelChildhoodCancer
Advocacy
Annual Summit
Awareness
AYA
Best Practices
Biorepositories
CAC2 News
CAC2 Projects
Call to Action
Clinical Trials
Collaboration
Data
Delayed Diagnosis
Digest
Drug Development
Drug Shortages
Ethics
Family Support
FDA
Global News
Member Access
Nutrition
Prevention
project incubator
Psychosocial Support
Rare Cancers
Regulations
Research
research advocacy collaboration
Survivorship
Venture Philanthropy
Recent Posts
- CAC2 Childhood Cancer Community News Digest (May 2-8)
- Guest Blog–National Cancer Institute Launches the CCDI Childhood Cancer Data Catalog
- CAC2 Childhood Cancer Community News Digest (April 25-May 1)
- CAC2 News–Great.com Interviews Coalition Against Childhood Cancer About A Future Without Childhood Cancers
- Community News–Congress Introduces the Childhood Cancer STAR Reauthorization Act